Carlos M. Viturro-Martinez
Toledo, CM 45007, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
Journal: Journal of medicinal chemistry
Published: November 16, 2020
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.
Journal: Bioorganic & medicinal chemistry letters
Published: November 02, 2015
Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.
Journal: Bioorganic & medicinal chemistry letters
Published: August 07, 2015
Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.
Journal: Bioorganic & medicinal chemistry letters
Published: May 18, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
Journal: ACS medicinal chemistry letters
Published: May 04, 2015
Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
Journal: Journal of medicinal chemistry
Published: December 16, 2014
Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).
Journal: Bioorganic & medicinal chemistry letters
Published: December 09, 2014
Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Journal: Journal of medicinal chemistry
Published: April 25, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026